$2995 | Single User
$4495 | Multi User
$8995 | Site License
$14995 | Global License

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017
[Report Updated: 01-10-2017]

Published by Current Partnering: 01 Oct 2017 | 119441 | In Stock
Related Topics: Abbott , AstraZeneca , Lilly , Novartis , Pfizer , Roche

Introduction

The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.


This report provides details of the latest preclinical agreements announced in the healthcare sector.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of over 2,000 preclinical stage partnering deals announced since 2010 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.


Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner preclinical stage compounds/products.


Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.


Chapter 5 provides a review of preclinical stage deal making since 2010. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.


Chapter 6 provides a detailed analysis of preclinical stage payment terms including headline, upfront, milestone and royalty rates.


Chapter 7 provides a review of the leading preclinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.


Chapter 8 provides a comprehensive listing of the top 50 most active preclinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.


Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2010, where a contract document is available in the public domain.


Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2010.


The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.


The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2010.


In addition, a comprehensive appendix of all preclinical deals since 2010 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.


Key benefits


Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 provides the reader with the following key benefits:


In-depth understanding of preclinical stage deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of preclinical stage agreements with numerous real life case studies

Insight into the terms included in a preclinical stage agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 is intended to provide the reader with an in-depth understanding and access to preclinical stage deal trends and structure of deals entered into by leading companies worldwide.


Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 includes:


Trends in preclinical stage dealmaking in the biopharma industry since 2010

Analysis of preclinical stage deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life preclinical stage deals

Access to over 2,000 preclinical stage deals

The leading preclinical stage deals by value since 2010

Most active preclinical stage dealmakers since 2010

The leading preclinical stage partnering resources


In Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017, the available contracts are listed by:


Company A-Z

Headline value

Stage of development at signing

Deal type

Specific therapy target


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 report provides comprehensive access to available deals and contract documents for over 2,000 preclinical stage deals. Analyzing actual contract agreements allows assessment of the following:


What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Table of Contents
for Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 [Report Updated: 01-10-2017]

  • Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Why do companies partner preclinical stage compounds?

    2.1. Introduction

    2.2. The role of preclinical stage partnering

    2.2.1. In-licensing at preclinical stage

    2.2.2. Out-licensing at preclinical stage

    2.3. Difference between discovery, preclinical and clinical stage deals

    2.4. Reasons for entering into preclinical stage partnering deals

    2.4.1. Licensors reasons for entering preclinical stage deals

    2.4.2. Licensees reasons for entering preclinical stage deals

    2.5. The future of preclinical stage partnering deals

    Chapter 3 – Preclinical stage deal strategies and structure

    3.1. Introduction

    3.2. At what stage do companies partner?

    3.2.1. Partnering early in pharmaceutical / biotech

    3.2.1.1. Discovery and preclinical stage partnering case studies

    3.2.1.1.a. Case study: LEO Pharma - 4SC

    3.2.1.1.b. Case study: Heptares Therapeutics - Cubist

    3.2.1.1.c. Case study: Incyte – Agenus Bio

    3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec

    3.2.2. Partnering later in pharmaceutical/biotech

    3.2.2.1. Clinical stage partnering case studies

    3.2.2.1.a. Case study: Servier – GeNeuro

    3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals

    3.2.2.1.c. Case study: AstraZeneca - Ardelyx

    3.2.2.1.d. Case study: Baxter – Onconova Therapeutics

    3.3. Early and later stage partnering – a risk/cost comparison

    3.4. What do companies spend on preclinical stage partnering?

    3.5. Pure versus multi-component partnering deals

    3.6. Pure licensing agreement structure

    3.6.1. Example pure preclinical stage licensing agreements

    3.6.1.a. Case study : Merck and Co. – Tesaro

    3.6.1.b. Case study : Marina Biotech – Mirna Therapeutics

    3.7. Multicomponent preclinical stage partnering agreements

    3.7.1. Example multicomponent preclinical stage clauses

    3.7.1.a. Case study: Eleven Biotherapeutics – ThromboGenics

    3.7.1.b. Case study: Pfizer – InSite Vision

    Chapter 4 – Preclinical stage partnering payment strategies

    4.1. Introduction

    4.2. Preclinical stage payment strategies

    4.3. Payment options

    4.3.1. Headline values

    4.3.2. Upfront payments

    4.3.2.1. Conditionality of upfront payments

    4.3.3. Loans

    4.3.4. Convertible loans

    4.3.5. Equity

    4.3.6. R&D funding

    4.3.7. Licensing fees

    4.3.8. Milestone payments

    4.3.9. Royalty payments

    4.3.9.1. Issues affecting royalty rates

    4.3.9.2. Royalties on combination products

    4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech

    4.3.9.3. Guaranteed minimum/maximum annual payments

    4.3.9.4. Royalty stacking

    4.3.9.5. Royalties and supply/purchase contracts

    4.3.10. Quids

    4.3.11. Option payments

    Chapter 5 – Trends in preclinical stage deal making

    5.1. Introduction

    5.2. Preclinical stage partnering over the years

    5.2.1. Attributes of preclinical deals

    5.3. Preclinical stage partnering by deal type

    5.4. Preclinical stage partnering by disease type

    5.5. Partnering by preclinical stage technology type

    5.6. Preclinical stage partnering by most active company since 2010

    Chapter 6 – Payment terms for preclinical stage partnering

    6.1. Introduction

    6.2. Guidelines for preclinical stage payment terms

    6.2.1. Upfront payments

    6.2.2. Milestone payments

    6.2.3. Royalty payments

    6.3. Preclinical stage payment terms – deal data analysis

    6.3.1. Public data

    6.3.2. Survey data

    6.4. Payment terms analysis

    6.4.1. Preclinical stage headline values

    6.4.2. Preclinical stage deal upfront payments

    6.4.3. Preclinical stage deal milestone payments

    6.4.4. Preclinical stage royalty rates

    Chapter 7 – Leading preclinical stage deals

    7.1. Introduction

    7.2. Top preclinical stage deals by value

    Chapter 8 – Top 50 most active preclinical stage dealmakers

    8.1. Introduction

    8.2. Top 50 most active preclinical stage dealmakers

    Chapter 9 – Preclinical stage partnering contracts directory

    9.1. Introduction

    9.2. Preclinical stage deals with contracts 2010 to 2017

    Chapter 10 – Preclinical stage deal making by development stage

    10.1. Introduction

    10.2. Deals by preclinical stage

    Appendices

    Appendix 1 – Preclinical stage dealmaking by companies A-Z

    Appendix 2 – Preclinical stage dealmaking by industry sector

    Appendix 3 – Preclinical stage dealmaking by stage of development

    Appendix 4 – Preclinical stage dealmaking by therapy area

    Appendix 5 – Preclinical stage dealmaking by technology type

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent titles from Current Partnering

    Table of figures

    Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking

    Figure 2: Agreements signed by phase of development (2010- 2017), % of all deals

    Figure 3: Components of the pure licensing deal structure

    Figure 4: Payment options for preclinical stage partnering deals

    Figure 5: Issues affecting royalty rates

    Figure 6: Preclinical stage partnering frequency since 2010

    Figure 7: Preclinical stage partnering by deal type since 2010

    Figure 8: Preclinical stage partnering by disease type since 2010

    Figure 9: Preclinical stage partnering by technology type since 2010

    Figure 10: Top 50 most active preclinical stage dealmakers since 2010

    Figure 11: Review of upfront payments for preclinical stage deals

    Figure 12: Review of milestone payments for preclinical stage deals

    Figure 13: Review of royalty payments for preclinical stage deals

    Figure 14: Preclinical stage deals with a headline value

    Figure 15: Preclinical stage deals with an upfront value

    Figure 16: Preclinical stage deals with a milestone value

    Figure 17: Preclinical stage deals with a royalty rate value

    Figure 18: Top preclinical stage deals by value since 2010

    Figure 19: Most active preclinical stage dealmakers since 2010

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

119441 | CP2057

Number of Pages

1000

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Preclinical Imaging Systems Market Research Report Forecast 2017 to 2022
Delivery of the Report will take 2-3 working days once order is placed.The Global Preclinical Imagin...
09 Oct 2017 by S&P Consulting USD $2,800 More Info
Global Preclinical Tomography System Market Analysis 2011-2017 and Forecast 2018-2023
SnapshotPreclinical Tomography System is used tomography technology to the visualization of living a...
07 Sep 2017 by 99Strategy USD $2,980 More Info
Global Preclinical Imaging Systems Market Research Report Forecast 2017 to 2022
Delivery of the Report will take 2-3 working days once order is placed.The Global Preclinical Imagin...
29 Jun 2017 by S&P Consulting USD $2,800 More Info
Global Preclinical Imaging Equipment Market Research Report Forecast 2017 to 2022
Delivery of the Report will take 2-3 working days once order is placed.The Global Preclinical Imagin...
29 Jun 2017 by S&P Consulting USD $2,800 More Info
Global Preclinical Tomography System Market Research 2011- 2022
SummaryPreclinical Tomography System is used tomography technology to the visualization of living an...
26 Jun 2017 by HeyReport USD $1,870 More Info
Global Preclinical Imaging Systems Market Research Report Forecast 2017 to 2022
Delivery of the Report will take 2-3 working days once order is placed.The Global Preclinical Imagin...
02 May 2017 by S&P Consulting USD $2,800 More Info
Global Preclinical Tomography System Market Analysis 2012-2017 and Forecast 2018-2023
SnapshotPreclinical Tomography System is used tomography technology to the visualization of living a...
06 Apr 2017 by 99Strategy USD $2,980 More Info
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016
The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016 report ...
01 Oct 2016 by Current Partnering USD $2,995 More Info
Pharmacovigilance Market: By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial); By Type of Service Providers (In House, Contract Outsourcing) & By Region-Forecast (2016-2022)
Pharmacovigilance is referred to as a practice of monitoring the effects of medical drugs after they...
23 Sep 2016 by Industry ARC USD $5,250 More Info
Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020
The global biosimulation market is expected to reach USD 2,107.99 million by 2020 from USD 1,034.93 ...
30 Jul 2015 by MarketsandMarkets USD $5,650 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 [Report Updated: 01-10-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)